FIG. 3.
Infection of mice with azole-resistant T.
cruzi. Mice were infected with either the parent clone (1 ×
104 trypomastigotes) or the in vitro-derived
fluconazole-resistant clone of T. cruzi (2 ×
106 trypomastigotes). Mice were treated with either placebo
or ketoconazole at 30 mg/kg by oral gavage for the first 7 days of
infection (four groups; n = 5 per group). The levels of
parasitemia were significantly different between the placebo-treated
(
) and ketoconazole-treated
(
) mice infected with the parent
line on all 3 days (P < 0.05), whereas the levels of
parasitemia were not significantly different between the
placebo-treated (▩) and ketoconazole-treated (■) mice infected with
the azole-resistant T. cruzi strain on all 3 days
(P > 0.10). hpf, high-power field.